<DOC>
	<DOCNO>NCT01215227</DOCNO>
	<brief_summary>The primary purpose extension study ass long-term safety tolerability preladenant participant parent study NCT01155466 [ P04938 ] NCT01227265 [ P07037 ] moderate severe Parkinson 's Disease ( PD ) . The study also characterize long-term efficacy preladenant participant PD . Participants continue receive stable regimen levodopa ( L-dopa ) plus adjunct medication study prescribed physician . Several class adjunct medication may use , include Amantadine , anticholinergic , dopa decarboxylase inhibitor , dopamine agonist .</brief_summary>
	<brief_title>An Active-Controlled Extension Study NCT01155466 P04938 NCT01227265 P07037 ( P06153 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Participants complete 12week treatment period parent trial , P04938 P07037 . Participants must willing able provide write informed consent P06153 . Participants must able adhere dose visit schedule . Participants must take Ldopa . Participants may take additional adjunct PD medication ( e.g. , dopamine agonist , entacapone ) . Each participant must result clinical laboratory test ( hematology , blood chemistry , urinalysis ) within normal limit clinically acceptable investigator evidence last available test result parent study ( P04938 P07037 ) , result fall within parameter exclusion describe exclusion criterion liverrelated finding . There change , find warrant checking , serology status ( cytomegalovirus [ CMV ] , EpsteinBarr virus [ EBV ] , Hepatitis B , C , E ) . Each participant must result physical examination within normal limit , include blood pressure , within normal limit clinically acceptable limit investigator , within parameter exclusion describe exclusion criterion blood pressure . All participant sexually active plan sexually active agree use highly effective method birth control participant study 2 week last dose study drug . A male participant must donate sperm within 2 week last dose study drug . Any participant discontinue P04938 P07037 reason . Any participant severe ongoing unstable medical condition ( e.g. , form clinically significant cardiac disease , symptomatic orthostatic hypotension , seizure , alcohol/drug dependence ) . Any participant history poorly control diabetes ( e.g. , hemoglobin A1c &gt; 8.5 ) significantly abnormal renal function ( e.g. , creatinine &gt; 2.0 mg/dL ) opinion investigator . As continuation liverrelated withdrawal criterion parent study ( P04938 P07037 ) , participant elevate value alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin ( T BIL ) , evidence recent chemistry panel result parent study , meet one follow criterion : ALT AST &gt; 8 x upper limit normal ( ULN ) . ALT AST &gt; 5 x ULN 2 week . ALT AST &gt; 3 x ULN ( TBIL &gt; 2 x ULN international normalize ratio [ INR ] &gt; 1.5 due anticoagulation ) visit . ALT AST &gt; 3 x ULN appearance worsen fatigue , nausea , vomit , right upper quadrant pain tenderness , fever , rash , and/or eosinophilia ( &gt; 5 % ) . As continuation blood pressure ( BP ) withdrawal criterion parent study ( P04938 P07037 ) , participant meeting follow criterion second two consecutive visit separate 7 day ( i.e. , participant meet one BP criterion already , 7 day P06153 screen visit ) : Systolic BP ≥ 180 mm Hg diastolic BP ≥ 105 mm Hg , An elevation baseline BP parent study ( P04938 P07037 ) systolic BP &gt; = 40 mm Hg diastolic BP ≥ 20 mm Hg . A participant must history within past 5 year primary recurrent malignant disease exception adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ prostate cancer normal prostatespecific antigen ( PSA ) post resection . Any participant average daily consumption three 4ounce glass ( 118 mL ) wine equivalent . A participant must receive certain prespecified medication ingest high tyraminecontaining age cheese ( e.g. , Stilton ) prespecified time window trial , trial , 2 week trial . Any participant allergy/sensitivity investigational product excipients . Any female participant breast feed consider breast feeding . Any female participant pregnant intend become pregnant . Any participant clinically significant condition situation , condition study , opinion investigator , would interfere trial evaluation optimal participation trial . Any participant member family member personnel investigational sponsor staff directly involve trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>